Biohaven Pharmaceutical Holding Company Ltd. (BHVN)
USD 36.0
(-7.98%)
USD 36.0
(-7.98%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 30.87 Million USD | 0.97% |
| 2022 | 30.58 Million USD | -95.12% |
| 2021 | 626.72 Million USD | 134.32% |
| 2020 | 267.45 Million USD | 0.0% |
| 2019 | - USD | -100.0% |
| 2018 | 117.51 Million USD | 0.0% |
| 2017 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 30.53 Million USD | -1.12% |
| 2024 Q2 | 29.74 Million USD | -2.58% |
| 2023 Q1 | 29.76 Million USD | -2.68% |
| 2023 Q2 | 29.11 Million USD | -2.17% |
| 2023 Q3 | 31.56 Million USD | 8.42% |
| 2023 FY | 30.87 Million USD | 0.97% |
| 2023 Q4 | 30.87 Million USD | -2.19% |
| 2022 Q4 | 30.58 Million USD | 487.64% |
| 2022 Q3 | 5.2 Million USD | 19.58% |
| 2022 Q2 | 4.35 Million USD | -99.31% |
| 2022 Q1 | 634.1 Million USD | 1.18% |
| 2022 FY | 30.58 Million USD | -95.12% |
| 2021 FY | 626.72 Million USD | 134.32% |
| 2021 Q1 | 270.75 Million USD | 1.23% |
| 2021 Q4 | 626.72 Million USD | 1.2% |
| 2021 Q3 | 619.26 Million USD | 125.9% |
| 2021 Q2 | 274.13 Million USD | 1.25% |
| 2020 Q2 | - USD | 0.0% |
| 2020 FY | 267.45 Million USD | 0.0% |
| 2020 Q3 | 264.13 Million USD | 0.0% |
| 2020 Q1 | - USD | 0.0% |
| 2020 Q4 | 267.45 Million USD | 1.26% |
| 2019 Q2 | - USD | 0.0% |
| 2019 FY | - USD | -100.0% |
| 2019 Q4 | - USD | 0.0% |
| 2019 Q3 | - USD | 0.0% |
| 2019 Q1 | - USD | -100.0% |
| 2018 Q4 | 117.51 Million USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2018 FY | 117.51 Million USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2017 Q1 | 5.09 Million USD | 0.0% |
| 2017 Q3 | - USD | -100.0% |
| 2017 Q2 | 4.78 Million USD | -6.01% |
| 2017 FY | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| ADC Therapeutics SA | 124.37 Million USD | 75.175% |
| Alto Neuroscience, Inc. | 151.46 Million USD | 79.614% |
| Annovis Bio, Inc. | - USD | -Infinity% |
| Ginkgo Bioworks Holdings, Inc. | 241.76 Million USD | 87.229% |
| Nuvation Bio Inc. | 4 Million USD | -670.577% |
| Nuvation Bio Inc. | 4 Million USD | -670.577% |
| Arcus Biosciences, Inc. | 11 Million USD | -180.7% |
| Theriva Biologics, Inc. | 2.15 Million USD | -1333.473% |
| Zymeworks Inc. | 26.72 Million USD | -15.549% |